These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 20627190

  • 1. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
    Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB.
    Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
    [Abstract] [Full Text] [Related]

  • 2. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S, Thephinlap C, Phisalaphong C, Porter JB, Fucharoen S.
    Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
    [Abstract] [Full Text] [Related]

  • 3. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
    Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.
    Blood; 2001 Feb 01; 97(3):792-8. PubMed ID: 11157499
    [Abstract] [Full Text] [Related]

  • 4. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB, Rafique R, Srichairatanakool S, Davis BA, Shah FT, Hair T, Evans P.
    Ann N Y Acad Sci; 2005 Feb 01; 1054():155-68. PubMed ID: 16339661
    [Abstract] [Full Text] [Related]

  • 5. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
    Kuo KH, Mrkobrada M.
    Hemoglobin; 2014 Feb 01; 38(6):409-21. PubMed ID: 25307964
    [Abstract] [Full Text] [Related]

  • 6. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y, Evans P, Manz CY, Porter JB.
    Haematologica; 2012 Jun 01; 97(6):835-41. PubMed ID: 22180427
    [Abstract] [Full Text] [Related]

  • 7. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
    Pepe A, Meloni A, Rossi G, Cuccia L, D'Ascola GD, Santodirocco M, Cianciulli P, Caruso V, Romeo MA, Filosa A, Pitrolo L, Putti MC, Peluso A, Campisi S, Missere M, Midiri M, Gulino L, Positano V, Lombardi M, Ricchi P.
    J Cardiovasc Magn Reson; 2013 Jan 16; 15(1):1. PubMed ID: 23324167
    [Abstract] [Full Text] [Related]

  • 8. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ.
    Hemoglobin; 2006 Jan 16; 30(2):183-200. PubMed ID: 16798643
    [Abstract] [Full Text] [Related]

  • 9. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 16; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 10. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 11. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.
    Br J Haematol; 1992 Oct 15; 82(2):431-6. PubMed ID: 1419825
    [Abstract] [Full Text] [Related]

  • 12. Pathogenesis and management of iron toxicity in thalassemia.
    Hershko C.
    Ann N Y Acad Sci; 2010 Aug 15; 1202():1-9. PubMed ID: 20712765
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S, Zhang W, Huang L, Jiang H.
    PLoS One; 2013 Aug 15; 8(12):e82662. PubMed ID: 24376563
    [Abstract] [Full Text] [Related]

  • 14. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Aug 15; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 15. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
    Chuang TY, Li JP, Weng TF, Wu KH, Chao YH.
    Ann Hematol; 2020 Oct 15; 99(10):2289-2294. PubMed ID: 32737633
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr 15; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 17. More pieces to the iron chelation puzzle.
    Waalen J.
    Transl Res; 2010 Aug 15; 156(2):53-4. PubMed ID: 20627189
    [No Abstract] [Full Text] [Related]

  • 18. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.
    Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI.
    Blood; 2000 May 01; 95(9):2975-82. PubMed ID: 10779448
    [Abstract] [Full Text] [Related]

  • 19. Combined therapy with deferoxamine and deferiprone.
    Kattamis A.
    Ann N Y Acad Sci; 2005 May 01; 1054():175-82. PubMed ID: 16339663
    [Abstract] [Full Text] [Related]

  • 20. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 May 01; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.